| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-Isoleucine-15N does not have a specific pharmacological target as it is a stable isotope-labeled tracer. L-Isoleucine is a non-polar hydrophobic essential amino acid involved in protein synthesis, muscle development and repair, and energy production. It is a precursor to succinyl CoA and acetyl CoA.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro activity of L-Isoleucine-15N is measured as its utility as a tracer in metabolic studies. In cell culture, the labeled amino acid is incorporated into proteins and metabolic intermediates, allowing for tracking via mass spectrometry. Its "activity" is reflected in its metabolic incorporation and its ability to serve as a probe for studying isoleucine metabolism. |
| ln Vivo |
In vivo, L-Isoleucine-15N is used to study isoleucine metabolism, protein synthesis, and branched-chain amino acid (BCAA) metabolism in living organisms. Administered orally or intravenously, the labeled amino acid is incorporated into proteins or metabolized through BCAA catabolic pathways. These studies provide quantitative data on isoleucine kinetics and its role in muscle metabolism and energy production.
|
| Enzyme Assay |
In vitro enzyme assays with L-Isoleucine-15N typically involve studying enzymes of branched-chain amino acid metabolism such as branched-chain aminotransferase (BCAT) and branched-chain alpha-keto acid dehydrogenase (BCKDH). The labeled substrate is incubated with enzyme preparations, and the reaction products are analyzed by mass spectrometry. These assays provide mechanistic insights into enzyme kinetics.
|
| Cell Assay |
In vitro cell culture experiments with L-Isoleucine-15N involve supplementing cell culture media with the labeled amino acid, often in isoleucine-free or defined media. Cells (e.g., muscle cells, hepatocytes) are cultured to allow incorporation of the label into proteins and metabolites. Following incubation, proteins or metabolites are extracted for analysis by mass spectrometry to study protein synthesis and BCAA metabolism.
|
| Animal Protocol |
In vivo animal experiments with L-Isoleucine-15N typically involve administering the labeled compound via oral gavage, injection, or dietary incorporation to rodents. Blood, tissues (muscle, liver), and excreta are collected at various time points. Isotopic enrichment of isoleucine and its metabolites is measured by mass spectrometry. These studies provide quantitative data on whole-body isoleucine metabolism.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of L-Isoleucine-15N are essentially identical to those of natural L-isoleucine. L-isoleucine is absorbed from the gastrointestinal tract via amino acid transporters, distributed throughout the body, and utilized in protein synthesis or metabolized through BCAA catabolic pathways. The 15N label allows for precise tracking of the compound's distribution and metabolism.
|
| Toxicity/Toxicokinetics |
L-Isoleucine-15N has a low toxicity profile since it is a naturally occurring essential amino acid. The 15N label is a stable, non-radioactive isotope and does not introduce additional toxicity. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance.
|
| References | |
| Additional Infomation |
L-Isoleucine-15N is a stable isotope-labeled form of the essential branched-chain amino acid L-isoleucine. It is used as a tracer to study isoleucine metabolism, protein synthesis, and muscle development. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only.
|
| Molecular Formula |
C6H1315NO2
|
|---|---|
| Molecular Weight |
132.17
|
| Exact Mass |
132.092
|
| CAS # |
59935-30-7
|
| Related CAS # |
L-Isoleucine;73-32-5
|
| PubChem CID |
10678279
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
168-170ºC(lit.)
|
| LogP |
1.144
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
103
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)O)[15NH2]
|
| InChi Key |
AGPKZVBTJJNPAG-NNXLWEQRSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/i7+1
|
| Chemical Name |
(2S,3S)-2-(15N)azanyl-3-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5660 mL | 37.8301 mL | 75.6601 mL | |
| 5 mM | 1.5132 mL | 7.5660 mL | 15.1320 mL | |
| 10 mM | 0.7566 mL | 3.7830 mL | 7.5660 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
